|Podcasts|March 3, 2011
Merck's Biosimilars Business, from Parexel's Perspective
Advertisement
Merck's Biosimilars Business, From Parexel's Perspective
Josef von Rickenbach, Chairman and CEO of Parexel, discusses why Parexel won the Merck biosimilars’ business, differences in recruitment for biosimilars, and trends for 2011, including the 20-year promise of technology now being realized.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway
2
Where AI Is Delivering Real Value in Clinical Trial Payments Right Now
3
ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems
4
From Doing to Reviewing: How a Connected Ecosystem Streamlines Clinical Trial Finance
5